FDA Determines Regulatory Review Period for EDURANT Patent Extension

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for EDURANT, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to a patent extension application submitted to the Director of Patents and Trademarks at the Department of Commerce.